<p>Assembly Biosciences, Inc.（纳斯达克代码：ASMB - 免费报告）- HC Wainwright 的股票研究分析师在 11 月 13 日（星期四）向投资者发布的研究报告中下调了 Assembly Biosciences 的 2027 财年每股收益（EPS）预期。HC Wainwright 分析师 P. Trucchio 现在预计这家生物制药公司将在该年度发布每股收益 1.44 美元，低于之前预测的 1.67 美元。HC Wainwright 对该股票给予 “买入” 评级，目标价为 50.00 美元。Assembly Biosciences 当前全年的共识收益预期为每股（6.87 美元）。HC Wainwright 还对 Assembly Biosciences 的 2029 财年收益进行了预估，预计为每股 3.09 美元。</p>
<p>Assembly Biosciences（纳斯达克代码：ASMB - 获取免费报告）最近在 11 月 10 日（星期一）发布了季度收益数据。这家生物制药公司报告该季度每股收益为（0.72 美元），低于共识预期的（0.50 美元）22 美分。Assembly Biosciences 的净利润率为负 117.20%，股本回报率为负 149.01%。该公司该季度的收入为 1079 万美元，而共识预期为 746 万美元。</p>
<p>获取 <strong>Assembly Biosciences</strong> 警报：</p>
<p>ASMB 已经成为多份研究报告的主题。Guggenheim 在 9 月 8 日（星期一）的研究报告中将 Assembly Biosciences 的目标价从 31.00 美元上调至 39.00 美元，并给予该公司 “买入” 评级。Citizens Jmp 在 9 月 24 日（星期三）的研究报告中开始覆盖 Assembly Biosciences。他们给予该公司 “跑赢大盘” 评级，目标价为 38.00 美元。Zacks Research 在 8 月 19 日（星期二）的研究报告中将 Assembly Biosciences 的评级上调至 “持有”。Weiss Ratings 在 10 月 8 日（星期三）的研究报告中重申了对 Assembly Biosciences 股票的 “卖出（d-）” 评级。最后，JMP Securities 在 9 月 24 日（星期三）的报告中开始覆盖 Assembly Biosciences 的股票。他们给予该公司 “市场跑赢” 评级，目标价为 38.00 美元。五位研究分析师对该股票给予 “买入” 评级，一位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat，Assembly Biosciences 目前的共识评级为 “适度买入”，平均目标价为 41.25 美元。</p>
<p><strong>获取我们关于 ASMB 的最新研究报告</strong></p>
<h2>Assembly Biosciences 股票表现</h2>
<p>纳斯达克代码：ASMB 的股票在星期一开盘价为 36.71 美元。该股票的市值为 2.8164 亿美元，市盈率为-6.58，贝塔值为 0.60。Assembly Biosciences 的 1 年最低价为 7.75 美元，1 年最高价为 37.71 美元。该公司的 50 日移动平均价格为 27.37 美元，200 日移动平均价格为 21.55 美元。</p>
<h2>对 Assembly Biosciences 的对冲基金看法</h2>
<p>几家机构投资者最近买入和卖出了该股票的股份。American Century Companies Inc.在第一季度购买了 Assembly Biosciences 的新股份，价值约 113,000 美元。Acadian Asset Management LLC 在第一季度将其在 Assembly Biosciences 的股份增加了 42.1%。Acadian Asset Management LLC 现在拥有 23,027 股这家生物制药公司的股票，价值 219,000 美元，此前在上个季度又购买了 6,823 股。Palumbo Wealth Management LLC 在第二季度将其在 Assembly Biosciences 的持股增加了 3.8%。Palumbo Wealth Management LLC 现在拥有 18,667 股这家生物制药公司的股票，价值 338,000 美元，此前在此期间又购买了 681 股。Geode Capital Management LLC 在第二季度将其在 Assembly Biosciences 的股份增加了 6.9%。Geode Capital Management LLC 现在拥有 51,015 股这家生物制药公司的股票，价值 925,000 美元，此前在上个季度又购买了 3,312 股。最后，Ellsworth Advisors LLC 在第三季度收购了 Assembly Biosciences 的新股份，价值 852,000 美元。目前 19.92% 的股票由机构投资者持有。</p>
<h2>关于 Assembly Biosciences</h2>
<p>（获取免费报告）</p>
<p>Assembly Biosciences, Inc.是一家生物技术公司，开发用于治疗病毒性疾病的治疗候选药物。它开发的 ABI-5366 是一种长效单纯疱疹病毒（HSV）解旋酶 - 引物抑制剂，目前正在进行 1a/1b 期临床试验，以治疗复发性生殖器疱疹；ABI-1179 也在进行 1a/1b 期临床试验，治疗复发性生殖器疱疹；ABI-6250 是一种小分子口服生物可用的肝炎δ病毒入侵抑制剂，目前正在进行 1a 期临床试验。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票，而不是 Assembly Biosciences</li>
<li>投资于高市盈率成长股</li>
<li>4 只寒冷天气股票，随着冬季消费升温而购买</li>
<li>能源和石油股票解析</li>
<li>迪士尼股票下跌——收益是否为 YouTube TV 和解铺平道路？</li>
<li>现在购买的 2 只金融科技股票和 1 只应避免的股票</li>
<li>Meta 的痛苦可能是你的收益：这是一个罕见的购买窗口吗？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVNNQg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVNNQg"/></p>
<p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Assembly Biosciences 吗？</h2>
<p>在你考虑 Assembly Biosciences 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Assembly Biosciences 并不在名单上。</p>
<p>虽然 Assembly Biosciences 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

Assembly生物科技

<p>HC Wainwright 分析师将 Assembly Biosciences 的 2027 财年每股收益预期从 1.67 美元下调至 1.44 美元，维持 “买入” 评级，目标价为 50 美元。目前全年的每股收益共识为 -6.87 美元。其他分析师的评级各不相同，整体共识为 “适度买入”，平均目标价为 41.25 美元。机构投资者在 ASMB 股票交易中活跃，开盘价为 36.71 美元，市值为 2.8164 亿美元</p>

<p>Assembly Biosciences, Inc. (NASDAQ:ASMB - Free Report) - Equities research analysts at HC Wainwright lowered their FY2027 earnings per share (EPS) estimates for Assembly Biosciences in a research note issued to investors on Thursday, November 13th. HC Wainwright analyst P. Trucchio now anticipates that the biopharmaceutical company will post earnings of $1.44 per share for the year, down from their prior forecast of $1.67. HC Wainwright has a &#34;Buy&#34; rating and a $50.00 price target on the stock. The consensus estimate for Assembly Biosciences' current full-year earnings is ($6.87) per share. HC Wainwright also issued estimates for Assembly Biosciences' FY2029 earnings at $3.09 EPS.</p>
<div class="lb-trans"><p>Assembly Biosciences, Inc.（纳斯达克代码：ASMB - 免费报告）- HC Wainwright 的股票研究分析师在 11 月 13 日（星期四）向投资者发布的研究报告中下调了 Assembly Biosciences 的 2027 财年每股收益（EPS）预期。HC Wainwright 分析师 P. Trucchio 现在预计这家生物制药公司将在该年度发布每股收益 1.44 美元，低于之前预测的 1.67 美元。HC Wainwright 对该股票给予 “买入” 评级，目标价为 50.00 美元。Assembly Biosciences 当前全年的共识收益预期为每股（6.87 美元）。HC Wainwright 还对 Assembly Biosciences 的 2029 财年收益进行了预估，预计为每股 3.09 美元。</p>
</div><p>Assembly Biosciences (NASDAQ:ASMB - Get Free Report) last posted its quarterly earnings data on Monday, November 10th. The biopharmaceutical company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.50) by ($0.22). Assembly Biosciences had a negative net margin of 117.20% and a negative return on equity of 149.01%. The business had revenue of $10.79 million for the quarter, compared to the consensus estimate of $7.46 million.</p>
<div class="lb-trans"><p>Assembly Biosciences（纳斯达克代码：ASMB - 获取免费报告）最近在 11 月 10 日（星期一）发布了季度收益数据。这家生物制药公司报告该季度每股收益为（0.72 美元），低于共识预期的（0.50 美元）22 美分。Assembly Biosciences 的净利润率为负 117.20%，股本回报率为负 149.01%。该公司该季度的收入为 1079 万美元，而共识预期为 746 万美元。</p>
</div><p>Get <strong>Assembly Biosciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Assembly Biosciences</strong> 警报：</p>
</div><p>ASMB has been the subject of a number of other research reports. Guggenheim increased their price objective on Assembly Biosciences from $31.00 to $39.00 and gave the company a &#34;buy&#34; rating in a research report on Monday, September 8th. Citizens Jmp assumed coverage on Assembly Biosciences in a research report on Wednesday, September 24th. They issued an &#34;outperform&#34; rating and a $38.00 price target for the company. Zacks Research raised Assembly Biosciences to a &#34;hold&#34; rating in a research note on Tuesday, August 19th. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Assembly Biosciences in a research note on Wednesday, October 8th. Finally, JMP Securities assumed coverage on shares of Assembly Biosciences in a report on Wednesday, September 24th. They issued a &#34;market outperform&#34; rating and a $38.00 target price for the company. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Assembly Biosciences currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $41.25.</p>
<div class="lb-trans"><p>ASMB 已经成为多份研究报告的主题。Guggenheim 在 9 月 8 日（星期一）的研究报告中将 Assembly Biosciences 的目标价从 31.00 美元上调至 39.00 美元，并给予该公司 “买入” 评级。Citizens Jmp 在 9 月 24 日（星期三）的研究报告中开始覆盖 Assembly Biosciences。他们给予该公司 “跑赢大盘” 评级，目标价为 38.00 美元。Zacks Research 在 8 月 19 日（星期二）的研究报告中将 Assembly Biosciences 的评级上调至 “持有”。Weiss Ratings 在 10 月 8 日（星期三）的研究报告中重申了对 Assembly Biosciences 股票的 “卖出（d-）” 评级。最后，JMP Securities 在 9 月 24 日（星期三）的报告中开始覆盖 Assembly Biosciences 的股票。他们给予该公司 “市场跑赢” 评级，目标价为 38.00 美元。五位研究分析师对该股票给予 “买入” 评级，一位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat，Assembly Biosciences 目前的共识评级为 “适度买入”，平均目标价为 41.25 美元。</p>
</div><p><strong>Get Our Latest Research Report on ASMB</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 ASMB 的最新研究报告</strong></p>
</div><h2>Assembly Biosciences Stock Performance</h2>
<div class="lb-trans"><h2>Assembly Biosciences 股票表现</h2>
</div><p>Shares of NASDAQ:ASMB opened at $36.71 on Monday. The stock has a market capitalization of $281.64 million, a price-to-earnings ratio of -6.58 and a beta of 0.60. Assembly Biosciences has a 1-year low of $7.75 and a 1-year high of $37.71. The company has a 50 day moving average price of $27.37 and a 200 day moving average price of $21.55.</p>
<div class="lb-trans"><p>纳斯达克代码：ASMB 的股票在星期一开盘价为 36.71 美元。该股票的市值为 2.8164 亿美元，市盈率为-6.58，贝塔值为 0.60。Assembly Biosciences 的 1 年最低价为 7.75 美元，1 年最高价为 37.71 美元。该公司的 50 日移动平均价格为 27.37 美元，200 日移动平均价格为 21.55 美元。</p>
</div><h2>Hedge Funds Weigh In On Assembly Biosciences</h2>
<div class="lb-trans"><h2>对 Assembly Biosciences 的对冲基金看法</h2>
</div><p>Several institutional investors have recently bought and sold shares of the stock. American Century Companies Inc. bought a new stake in shares of Assembly Biosciences during the 1st quarter worth about $113,000. Acadian Asset Management LLC lifted its stake in shares of Assembly Biosciences by 42.1% in the first quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company's stock worth $219,000 after buying an additional 6,823 shares during the last quarter. Palumbo Wealth Management LLC boosted its holdings in shares of Assembly Biosciences by 3.8% during the 2nd quarter. Palumbo Wealth Management LLC now owns 18,667 shares of the biopharmaceutical company's stock worth $338,000 after buying an additional 681 shares during the period. Geode Capital Management LLC grew its stake in Assembly Biosciences by 6.9% in the 2nd quarter. Geode Capital Management LLC now owns 51,015 shares of the biopharmaceutical company's stock valued at $925,000 after buying an additional 3,312 shares during the last quarter. Finally, Ellsworth Advisors LLC acquired a new position in Assembly Biosciences during the 3rd quarter worth $852,000. 19.92% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>几家机构投资者最近买入和卖出了该股票的股份。American Century Companies Inc.在第一季度购买了 Assembly Biosciences 的新股份，价值约 113,000 美元。Acadian Asset Management LLC 在第一季度将其在 Assembly Biosciences 的股份增加了 42.1%。Acadian Asset Management LLC 现在拥有 23,027 股这家生物制药公司的股票，价值 219,000 美元，此前在上个季度又购买了 6,823 股。Palumbo Wealth Management LLC 在第二季度将其在 Assembly Biosciences 的持股增加了 3.8%。Palumbo Wealth Management LLC 现在拥有 18,667 股这家生物制药公司的股票，价值 338,000 美元，此前在此期间又购买了 681 股。Geode Capital Management LLC 在第二季度将其在 Assembly Biosciences 的股份增加了 6.9%。Geode Capital Management LLC 现在拥有 51,015 股这家生物制药公司的股票，价值 925,000 美元，此前在上个季度又购买了 3,312 股。最后，Ellsworth Advisors LLC 在第三季度收购了 Assembly Biosciences 的新股份，价值 852,000 美元。目前 19.92% 的股票由机构投资者持有。</p>
</div><h2>About Assembly Biosciences</h2>
<div class="lb-trans"><h2>关于 Assembly Biosciences</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.</p>
<div class="lb-trans"><p>Assembly Biosciences, Inc.是一家生物技术公司，开发用于治疗病毒性疾病的治疗候选药物。它开发的 ABI-5366 是一种长效单纯疱疹病毒（HSV）解旋酶 - 引物抑制剂，目前正在进行 1a/1b 期临床试验，以治疗复发性生殖器疱疹；ABI-1179 也在进行 1a/1b 期临床试验，治疗复发性生殖器疱疹；ABI-6250 是一种小分子口服生物可用的肝炎δ病毒入侵抑制剂，目前正在进行 1a 期临床试验。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Assembly Biosciences</li>
<li>Investing in the High PE Growth Stocks</li>
<li>4 Cold-Weather Stocks to Buy as Winter Spending Heats Up</li>
<li>Energy and Oil Stocks Explained</li>
<li>Disney Stock Drops—Will Earnings Pave Way for a YouTube TV Truce?</li>
<li>2 Fintech Stocks to Buy Now and 1 to Avoid</li>
<li>Meta’s Pain May Be Your Gain: Is This a Rare Buying Window?</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，而不是 Assembly Biosciences</li>
<li>投资于高市盈率成长股</li>
<li>4 只寒冷天气股票，随着冬季消费升温而购买</li>
<li>能源和石油股票解析</li>
<li>迪士尼股票下跌——收益是否为 YouTube TV 和解铺平道路？</li>
<li>现在购买的 2 只金融科技股票和 1 只应避免的股票</li>
<li>Meta 的痛苦可能是你的收益：这是一个罕见的购买窗口吗？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVNNQg" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=ASMB"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Assembly Biosciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Assembly Biosciences 吗？</h2>
</div><p>Before you consider Assembly Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Assembly Biosciences 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Assembly Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Assembly Biosciences 并不在名单上。</p>
</div><p>While Assembly Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Assembly Biosciences 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

HC Wainwright 发布了对 Assembly Biosciences 2027 财年收益的预估